Marin Kollef, MD
Pulmonary Disease · Saint Louis, MONPI 1326077165
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (47.9%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. 13 manufacturers reported payments, led by Merck at 47.2% of the total. Reporting peaked in 2019 at $170,049 and has fallen 94.2% since, to $9,900 in 2025. Among pulmonary disease clinicians in MO with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 299 payments — averaging $883.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Merck$125K
- Shionogi Inc$57K
- AbbVie$49K
- Tetraphase Pharmaceuticals, Inc.$12K
- Pfizer$9K
- Sage Therapeutics, LLC$4K
- plus $9K from 7 others
Across 1 payment — averaging $3200.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Pfizer$3K
What the payments were for
- Consulting fees$83,06231%
- Speaking & faculty fees$126,45148%
- Travel & lodging$50,14919%
- Food & beverage$4,3682%
- Gifts$90%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Merck | 150 | $124,753 |
| Shionogi Inc | 35 | $57,146 |
| AbbVie | 91 | $48,967 |
| Tetraphase Pharmaceuticals, Inc. | 8 | $11,866 |
| Pfizer | 7 | $8,793 |
| Sage Therapeutics, LLC | 1 | $3,600 |
| La Jolla Pharmaceutical Company | 1 | $2,815 |
| Acelrx Pharmaceuticals, Inc. | 1 | $2,250 |
| GSK | 1 | $1,557 |
| Cidara Therapeutics, Inc. | 1 | $1,225 |
| Grifols Therapeutics LLC | 1 | $950 |
| Accelerate Diagnostics Inc. | 1 | $78 |
| Biomerieux Inc | 1 | $40 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$264,040 in reported general payments places this provider in the 95th percentile of 295 pulmonary disease providers in Missouri.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other pulmonary disease in Saint Louis
- Derek ByersSaint Louis$835K
- Alexander ChenSaint Louis$679K
- Joseph OjileSaint Louis$538K
- Edward CharbekSaint Louis$372K
- Praveen ChennaSaint Louis$255K
- Murali ChakinalaSaint Louis$172K
- Janet LeeSaint Louis$143K
- Ali SadoughiSaint Louis$87K
- Ramsey HachemSaint Louis$79K
- Shiraz DaudSaint Louis$67K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.